The Impact of Medicare Part D on Pharmaceutical R&D
---- Acknowledgements -----
This work was supported in part by the RAND Roybal Center for Health Policy Simulation, funded by the National Institute on Aging grant 5P30AG024968. The authors also gratefully acknowledge partial financial support to M. Blume-Kohout from the Kip & Mary Ann Hagopian and Anne & James Rothenberg dissertation awards at Pardee RAND Graduate School, and to N. Sood from the Bing Center for Health Economics at RAND. The views expressed herein are those of the author(s) and do not necessarily reflect the views of the National Bureau of Economic Research.